Negative methylation status of Vimentin predicts improved prognosis in pancreatic carcinoma

Table 1 Clinicopathological features of pancreatic carcinoma n (%)

Data	Vimentin methylated negative group (n = 43)2	Vimentin methylated positive group (n = 21)3	P value
Sex			0.582
Male	27 (62.8)	15 (71.4)
Female	16 (37.2)	6 (28.6)
Tumor position			0.007
Head	11 (25.6)	13 (61.9)
Body and tail	32 (74.4)	8 (38.1)
Preoperative CEA level			0.294
Normal	20 (46.5)	13 (61.9)
Elevated	23 (53.5)	8 (38.1)
Preoperative CA19-9 level			0.600
Normal	24 (55.8)	10 (47.6)
Elevated	19 (44.2)	11 (52.4)
Pathological N staging1			0.426
N0	21(48.8)	13 (61.9)
N1	22 (51.2)	8 (38.1)
Pathological T staging1			0.753
T1	14 (32.6)	5 (23.8)
T2	19 (44.2)	11 (52.4)
T3	10 (23.3)	5 (23.8)
Adjuvant chemotherapy			0.791
No	20 (46.5)	11 (52.4)
Yes	23 (53.5)	10 (47.6)

¹The pathological T and N staging was based on the UICC staging systems for pancreatic cancer;

²Median age 54 years, range: 36-71 years;

³Median age 53 years, range: 41-68 years.